Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study Kezar Life Sciences halted its PALIZADE Phase 2b lupus ...

Anavex Life Sciences (NASDAQ:AVXL) is a short-squeeze candidate because its share prices are rising on good news, institutional and analyst support is growing, and the short-sellers are selling ...